S&P 500   5,087.03 (+2.11%)
DOW   39,069.11 (+1.18%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.71%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.64 (-0.03%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
S&P 500   5,087.03 (+2.11%)
DOW   39,069.11 (+1.18%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.71%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.64 (-0.03%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
S&P 500   5,087.03 (+2.11%)
DOW   39,069.11 (+1.18%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.71%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.64 (-0.03%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
S&P 500   5,087.03 (+2.11%)
DOW   39,069.11 (+1.18%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.71%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.64 (-0.03%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
NASDAQ:CBIO

Catalyst Biosciences (CBIO) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.34
$7.67
52-Week Range
N/A
Volume
32,246 shs
Average Volume
763,526 shs
Market Capitalization
$291.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CBIO stock logo

About Catalyst Biosciences Stock (NASDAQ:CBIO)

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.


CBIO Stock News Headlines

Best way to buy gold today (not what you'd think)
With so many strange events happening across the economy (longest bear market for bonds since Civil War... unprecedented bank closures... and soaring prices) – it's no wonder the richest investors are loading up on gold. But what you might not realize is there's a much better way to profit from rising gold prices – without ever touching an ETF, mining stock, or even bullion.
Why Banks Could See a "Cash Frenzy" on March 11
He called the Lehman Brothers collapse in 2008… the Bitcoin crash in 2018… and the inflation crisis of 2022. Now, he's warning that the 2023 banking crisis is not over yet. Instead, we could see a cash frenzy at banks as soon as March 11. Do NOT buy another stock until you
CBIO - Catalyst Biosciences, Inc.
5 Cheap Healthcare Stocks to Buy in 2023
12 Cheap Healthcare Stocks to Buy in 2023
Catalyst Biosciences Provides Corporate Update
Catalyst/Millburn Hedge Strategy I
5 Stocks with the Lowest PE Ratio
See More Headlines
Receive CBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/17/2023
Today
2/22/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CBIO
CUSIP
87611R30
Employees
7
Year Founded
2003

Profitability

Net Income
$-8,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$790,000.00
Book Value
($0.78) per share

Miscellaneous

Free Float
36,869,000
Market Cap
$291.29 million
Optionable
Optionable
Beta
1.05

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Nassim Usman Ph.D. (Age 63)
    President, CEO & Director
    Comp: $1.75M
  • Ms. Seline E. Miller CPA (Age 54)
    Senior VP of Finance, Interim Chief Financial & Principal Accounting Officer
    Comp: $707.55k
  • Ms. Ana Kapor
    Senior Director of Investor Relations & Corporate Communications














CBIO Stock Analysis - Frequently Asked Questions

When is Catalyst Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our CBIO earnings forecast
.

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences, Inc. (NASDAQ:CBIO) posted its quarterly earnings data on Thursday, August, 17th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07).

When did Catalyst Biosciences' stock split?

Shares of Catalyst Biosciences reverse split before market open on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Catalyst Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Biosciences investors own include Baozun (BZUN), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO), Amarin (AMRN), ImmunoGen (IMGN), Sarepta Therapeutics (SRPT), VBI Vaccines (VBIV), Biocept (BIOC) and Imunon (CLSN).

Who are Catalyst Biosciences' major shareholders?

Catalyst Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

This page (NASDAQ:CBIO) was last updated on 2/22/2024 by MarketBeat.com Staff